Arafah Maha
Department of Pathology, King Saud University, Riyadh, Saudi Arabia.
Turk Patoloji Derg. 2012;28(1):38-43. doi: 10.5146/tjpath.2012.01095.
Data on Hormone Receptor and Her-2/neu expression in breast cancers from Saudi Arabia and Gulf Region is sparse. We undertook this study to describe the patterns of hormone receptor and Her-2/neu protein expression in breast carcinoma and compared them with the histological grade at a University Hospital in Riyadh.
We conducted a retrospective study on 164 invasive ductal carcinoma of breast between the year 2002 and 2008. Immunohistochemical analysis for Estrogen and Progesterone Receptor and Her-2/neu was done in all the cases. Fluorescent in situ hybridization for Her-2/neu gene amplification was performed in all 2+ cases and few equivocal 1+ and 3+cases by immunohistochemistry. Correlation between Estrogen and Progesterone Receptor and Her-2/ neu amplification and grade of tumor was calculated.
The expression of Estrogen Receptor, Progesterone Receptor were significantly correlated (p < 0.001). Also, there was a significant negative correlation between expression of hormone receptor and Her-2/neu amplification. The histologic grade of the tumor was significantly correlated to the expression of both Estrogen and Progesterone Receptor. However, the relationship between Her-2/ neu amplification and grade was not significant and many of the grade III tumor were Her-2/neu negative. In addition, Her-2/neu gene amplification by fluorescent in situ hybridization was observed in 84.6% of breast cancer that were 3+ and in 18.75 % cases that were 2+ by immunohistochemistry.
Prevalence of Estrogen and Progesterone Receptor expression and Her-2/neu amplification in breast cancer in the Saudi Arabian population is similar to that reported internationally. There is a negative correlation between hormone receptors expression and Her-2/neu amplification. However not all of the high-grade breast cancers showed Her-2/neu positive status.
沙特阿拉伯和海湾地区乳腺癌中激素受体及人表皮生长因子受体2(Her-2/neu)表达的数据较为稀少。我们开展此项研究以描述乳腺癌中激素受体及Her-2/neu蛋白的表达模式,并将其与利雅得一家大学医院的组织学分级进行比较。
我们对2002年至2008年间的164例乳腺浸润性导管癌进行了回顾性研究。对所有病例进行了雌激素受体、孕激素受体及Her-2/neu的免疫组织化学分析。对所有免疫组织化学检测为2+的病例以及少数可疑的1+和3+病例进行了Her-2/neu基因扩增的荧光原位杂交检测。计算了雌激素受体、孕激素受体及Her-2/neu扩增与肿瘤分级之间的相关性。
雌激素受体和孕激素受体的表达显著相关(p<0.001)。此外,激素受体表达与Her-2/neu扩增之间存在显著负相关。肿瘤的组织学分级与雌激素和孕激素受体的表达均显著相关。然而,Her-2/neu扩增与分级之间的关系并不显著,许多III级肿瘤Her-2/neu呈阴性。此外,荧光原位杂交检测显示,免疫组织化学检测为3+的乳腺癌中有84.6%存在Her-2/neu基因扩增,2+的病例中有18.75%存在该扩增。
沙特阿拉伯人群乳腺癌中雌激素和孕激素受体表达及Her-2/neu扩增的患病率与国际报道相似。激素受体表达与Her-2/neu扩增之间存在负相关。然而,并非所有高级别乳腺癌均显示Her-2/neu阳性状态。